These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22645177)

  • 1. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
    Weng J; Rawal S; Chu F; Park HJ; Sharma R; Delgado DA; Fayad L; Fanale M; Romaguera J; Luong A; Kwak LW; Neelapu SS
    Blood; 2012 Aug; 120(8):1613-23. PubMed ID: 22645177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
    Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
    Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
    Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
    Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues.
    Narducci MG; Pescarmona E; Lazzeri C; Signoretti S; Lavinia AM; Remotti D; Scala E; Baroni CD; Stoppacciaro A; Croce CM; Russo G
    Cancer Res; 2000 Apr; 60(8):2095-100. PubMed ID: 10786666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.
    Herling M; Patel KA; Hsi ED; Chang KC; Rassidakis GZ; Ford R; Jones D
    Am J Surg Pathol; 2007 Jul; 31(7):1123-9. PubMed ID: 17592280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.
    Schmidt SM; Schag K; Müller MR; Weck MM; Appel S; Kanz L; Grünebach F; Brossart P
    Blood; 2003 Jul; 102(2):571-6. PubMed ID: 12576330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.
    Said JW; Hoyer KK; French SW; Rosenfelt L; Garcia-Lloret M; Koh PJ; Cheng TC; Sulur GG; Pinkus GS; Kuehl WM; Rawlings DJ; Wall R; Teitell MA
    Lab Invest; 2001 Apr; 81(4):555-64. PubMed ID: 11304575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
    Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
    Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
    Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
    Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
    Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.
    Martorelli D; Guidoboni M; De Re V; Muraro E; Turrini R; Merlo A; Pasini E; Caggiari L; Romagnoli L; Spina M; Mortarini R; Gasparotto D; Mazzucato M; Carbone A; Rosato A; Anichini A; Dolcetti R
    Clin Cancer Res; 2012 Aug; 18(15):4080-91. PubMed ID: 22705988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
    Maia S; Haining WN; Ansén S; Xia Z; Armstrong SA; Seth NP; Ghia P; den Boer ML; Pieters R; Sallan SE; Nadler LM; Cardoso AA
    Cancer Res; 2005 Nov; 65(21):10050-8. PubMed ID: 16267031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
    Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
    Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human CD8 and CD4 T cell epitopes of epithelial cancer antigens.
    Sato N; Nabeta Y; Kondo H; Sahara H; Hirohashi Y; Kashiwagi K; Kanaseki T; Sato Y; Rong S; Hirai I; Kamiguchi K; Tamura Y; Matsuura A; Takahashi S; Torigoe T; Ikeda H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S86-90. PubMed ID: 10950155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
    Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
    Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.